药物
|
公司
|
治疗领域
|
年
|
Obeticholic acid (Ocaliva)
|
Intercept Pharmaceuticals, Sumitomo Dainippon Pharma
|
肝病
|
2016
|
Pimavanserin (Nuplazid)
|
ACADIA Pharmaceuticals
|
神经病学/精神病学
|
2016
|
Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey)
|
Gilead Sciences Inc., Janssen R&D
|
传染病
|
2016
|
Selexipag (Uptravi)
|
Actelion, Nippon Shinyaku Co.
|
心血管疾病
|
2016
|
Venetoclax (Venclexta; Venclyxto)
|
AbbVie Inc.
|
肿瘤
|
2016
|
Alirocumab (Praluent)
|
Regeneron Pharmaceuticals Inc., Sanofi SA
|
心血管疾病
|
2015
|
Brexpiprazole (Rexulti)
|
Lundbeck, Otsuka Pharmaceutical
|
神经病学/精神病学
|
2015
|
Evolocumab (Repatha)
|
Amgen, Astellas Pharma Inc.
|
心血管疾病
|
2015
|
Gardasil 9 vaccine
|
Merck & Co.
|
传染病
|
2015
|
Insulin glargine (Toujeo)
|
Sanofi SA
|
内分泌/代谢疾病
|
2015
|
Lumacaftor plus ivacaftor (Orkambi)
|
Vertex Pharmaceuticals Inc.
|
呼吸系统疾病
|
2015
|
Nivolumab (Opdivo)
|
Bristol-Myers Squibb Co.
|
肿瘤
|
2015
|
Palbociclib (Ibrance)
|
Pfizer Inc.
|
肿瘤
|
2015
|
Sacubitril plus valsartan (LCZ-696)
|
Novartis International AG
|
心血管疾病
|
2015
|
Secukinumab (Cosentyx)
|
Novartis International AG
|
过度免疫反应/自身免疫病
|
2015
|
Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak)
|
AbbVie Inc.
|
呼吸系统疾病
|
2015
|
Idelalisib (Zydelig)
|
Gilead Sciences Inc.
|
肿瘤
|
2014
|
Sofosbuvir (Sovaldi)
|
Gilead Sciences Inc.
|
传染病
|
2014
|
Vilanterol plus umeclidinium (Anoro Ellipta)
|
GlaxoSmithKline plc, Theravance Biopharma Inc.
|
呼吸系统疾病
|
2014
|
Apremilast (Otezla)
|
Celgene Corporation
|
过度免疫反应/自身免疫病
|
2013
|
Fluticasone furoate plus vilanterol trifenatate (Relovair)
|
GlaxoSmithKline plc, Theravance Biopharma Inc.
|
呼吸系统疾病
|
2013
|
Icosapent ethyl ester (Vascepa)
|
Amarin Corporation plc
|
心血管疾病
|
2013
|
Pomalidomide (Pomalyst)
|
Celgene Corporation
|
肿瘤
|
2013
|
Trastuzumab emtansine (T-DM1)
|
Roche
|
肿瘤
|
2013
|
Umeclidinium plus vilanterol (Zephyr)
|
GlaxoSmithKline plc, Theravance Biopharma Inc.
|
呼吸系统疾病
|
2013
|